Edwards Lifesciences (NYSE:EW) VP Donald Bobo, Jr. Sells 22,680 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 22,680 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $80.85 on Friday. The stock’s 50-day simple moving average is $81.71 and its 200-day simple moving average is $81.72. The firm has a market capitalization of $46.61 billion, a PE ratio of 44.18, a price-to-earnings-growth ratio of 2.12 and a beta of 0.95. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. UBS Group reissued a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.96.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $266,000. Westerkirk Capital Inc. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $493,000. Beacon Pointe Advisors LLC lifted its position in shares of Edwards Lifesciences by 3.4% during the 2nd quarter. Beacon Pointe Advisors LLC now owns 30,359 shares of the medical research company’s stock valued at $2,374,000 after acquiring an additional 995 shares during the period. Groupe la Francaise raised its holdings in Edwards Lifesciences by 719.4% during the second quarter. Groupe la Francaise now owns 19,174 shares of the medical research company’s stock worth $1,493,000 after purchasing an additional 16,834 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $209,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.